Osteoarthritis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies

"DelveInsight's, "Osteoarthritis Pipeline Insight, 2022," report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis Pipeline landscape"

It covers the Osteoarthritis Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Osteoarthritis emerging drugs, the Osteoarthritis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Osteoarthritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key takeaways from the Osteoarthritis Pipeline Insight Report
• DelveInsight's Osteoarthritis Pipeline analysis depicts the space with 130+ active players working to develop 130+ pipeline therapies.
• The Osteoarthritis pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
• Osteoarthritis Pipeline Companies included Ampio Pharmaceuticals, Biosplice Therapeutics, Symic Bio, UnicoCell Biomed CO. LTD, Eupraxia Pharmaceuticals Inc., Eli Lilly and Company, Xalud Therapeutics, Inc., ICM Biotech Australia Pty Ltd., Taiwan Liposomal Company, Gwo Xi Stem Cell Applied Technology Co., Ltd., K-STEMCELL, Centrexion Therapeutics, and many others.
• Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug.

Get to know more in-depth information about the Osteoarthritis Pipeline Report, click here: https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteoarthritis Overview

Osteoarthritis is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected.
The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints. The pain tends to be worse when the person move the joint or at the end of the day. Osteoarthritis is a leading cause of disability and source of societal cost in older adults. With an ageing and increasingly obese population, this syndrome is becoming even more prevalent than in previous decades.

Osteoarthritis Pipeline Insight Report

Osteoarthritis Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Osteoarthritis Emerging Drugs
• Lorecivivint: Biosplice Therapeutics
• CYP 004: Cynata Therapeutics
• JTA-004: Bone Therapeutics
• SMUP-IA-01: Medipost
• TTAX03: Tissue Tech

Osteoarthritis Pipeline Therapeutics Analysis
There are approx. 130+ key companies which are developing therapies for Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

For further information about Osteoarthritis Treatment and pipeline therapies, visit @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteoarthritis Pipeline Phases
DelveInsight's report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Osteoarthritis Pipeline development activities
The report provides insights into:
• All of the companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Osteoarthritis
• Osteoarthritis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Osteoarthritis
The Osteoarthritis Pipeline Report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Table of Content
1. Introduction
2. Executive Summary
3. Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Osteoarthritis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Mid Stage Products (Phase II)
10. TTAX03: Tissue Tech
11. Early Stage Products (Phase I)
12. GLPG-0555: Gilead Sciences
13. Preclinical Stage Products
14. Protego-PD: Plakous Therapeutics
15. Inactive Products
16. Osteoarthritis Key Companies
17. Osteoarthritis Key Products
18. Osteoarthritis- Unmet Needs
19. Osteoarthritis- Market Drivers and Barriers
20. Osteoarthritis- Future Perspectives and Conclusion
21. Osteoarthritis Analyst Views
22. Osteoarthritis Key Companies
23. Appendix

Got Queries? Reach out for more information on the Osteoarthritis Pipeline Report @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.